



Bulletin from the extraordinary general meeting in Klaria Pharma Holding AB (publ)

At the extraordinary general meeting held in Klaria Pharma Holding AB (publ) today on 30 December 2021, it was resolved (all in accordance with the proposals presented in the notice to attend the meeting kept available at the company's website www.klaria.com):

- It was resolved to approve an addendum agreement with FFT Medical AB in order to finally settle the purchase price for Klaria's acquisition of all shares in Uppsalagruppen Medical AB from FFT Medical AB during 2019. In light of Fredrik Hübinette, chairman of the board of Klaria, owning over 20 per cent of the shares in FFT Medical AB, FFT Medical AB is considered a closely related party to Klaria in accordance with Chapter 16a Section 3 of the Swedish Companies Act, and in accordance with Chapter 16a Section 7 of the Swedish Companies Act, the agreement was thus submitted to the general meeting for approval.
- It was resolved to increase the share capital by no more than SEK 35,977.967315 through the issuance of no more than 2,158,678 new shares directed to FFT Medical AB as payment in accordance with the above mentioned addendum agreement.
- It was resolved to implement a long-term incentive programme for employees and consultants including a directed issue of warrants and approval of transfer of warrants.

Stockholm, December 2021

Klaria Pharma Holding AB (publ)

For more information, visit the Klaria Pharma Holding website klaria.com or contact:

investor.relations@klaria.com

Tel: +46 (0) 8-446 42 99

This is Klaria Pharma Holding AB

Klaria (Klaria Pharma Holding AB) is a Swedish listed pharmaceutical company that develops innovative, rapid-acting products. By combining patented technology of a film that attaches to the oral mucosa and well proven pharmaceuticals, the company has developed a drug distribution concept with many benefits and potential uses. Klaria is listed on Nasdaq First North Growth Markets under the short name KLAR. FNCA Sweden is Certified Advisor (info@fnca.se, +46(0) 8-528 00 399) for Klaria Pharma Holding AB. For more information, see www.klaria.com.